Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company based in Needham, Massachusetts, has recently disclosed its third-quarter financial results for 2026. The company, which specializes in developing oncolytic viral immunotherapies for cancer treatment, reported that its cash and cash equivalents stand at approximately $203 million. This financial position is expected to support the company’s operations through the second quarter of 2028.
In a significant regulatory development, Candel Therapeutics is actively engaging in discussions with the FDA regarding a Biologics License Application (BLA) for its prostate-cancer therapy. The company has outlined plans to submit the BLA in mid-2027, marking a critical step towards potential commercialization.
Recent clinical updates from Candel Therapeutics have been presented at the Society for Immunotherapy of Cancer meeting. The company showcased data for its two leading therapies, aglatimagene and linoserpaturev, across various cancer types, including prostate cancer, non-small-cell lung cancer, and high-grade glioma. Notably, the phase-2a results for lung cancer have been published, and updated phase-1b data for linoserpaturev have indicated promising long-term survival signals.
On the corporate front, Candel Therapeutics has announced new board appointments, reinforcing its leadership team. The company has also strengthened its regulatory and quality leadership in preparation for the upcoming BLA submission and potential commercial launch.
Financially, Candel Therapeutics is listed on the Nasdaq with a market capitalization of approximately $705.5 million. The company’s stock closed at $6.2 on November 12, 2026, with a 52-week high of $14 on August 26, 2026, and a 52-week low of $4.35 on November 24, 2025. The price-to-earnings ratio stands at -5.95, reflecting the company’s current financial metrics.
As Candel Therapeutics continues to advance its clinical and regulatory milestones, it remains focused on its mission to develop innovative therapies for cancer patients, leveraging its expertise in oncolytic viral immunotherapies.
